Loading...
Market
What will Immutep's stock price be at the end of 2024?
2
Resolution / Starting Odds
Below $5 • 25%
$5 - $10 • 25%
$10 - $15 • 25%
Above $15 • 25%
Stock market data from financial news and stock market platforms
Story
Immutep Reports Positive Results in PD-L1-Negative Head and Neck Cancer with Eftilagimod Alpha and Pembrolizumab
Jul 12, 2024, 01:54 PM
Immutep has reported positive results in first-line treatment of head and neck squamous cell carcinoma (HNSCC) patients with negative PD-L1 expression. The results were achieved using a combination of Eftilagimod Alpha and Pembrolizumab, which generated a favorable overall response rate (ORR). This announcement has led to an 18.4% pre-market increase in Immutep's stock price ($IMMP). The findings were highlighted during the ESMO Virtual Plenary and have been met with significant interest in the oncology community. The results were reported by SI.
View original story
Similar markets
Below $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
Above $40 • 25%
Less than current price • 25%
Current price to 20% higher • 25%
20% to 50% higher • 25%
More than 50% higher • 25%
Decrease by more than 10% • 25%
Change between -10% and 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Less than $500 • 25%
$500 to $600 • 25%
$600 to $700 • 25%
More than $700 • 25%
Below $5 • 25%
$5 to $7.50 • 25%
$7.51 to $10 • 25%
Above $10 • 25%
Below €10 • 25%
€10 - €20 • 25%
€20 - €30 • 25%
Above €30 • 25%
Below $20 • 25%
$20 to $40 • 25%
$40 to $60 • 25%
Above $60 • 25%
Below $150 • 25%
$150 - $175 • 25%
$175 - $200 • 25%
Above $200 • 25%
Below $100 • 25%
$100 - $150 • 25%
$150 - $200 • 25%
Above $200 • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Below $20 • 25%
$20 to $40 • 25%
$40 to $60 • 25%
Above $60 • 25%
Below $900 • 25%
$900 to $950 • 25%
$950 to $1000 • 25%
Above $1000 • 25%